Differential association of plasma monocyte chemoattractant protein-1 with systemic inflammatory and airway remodeling biomarkers in type-2 diabetic patients with and without asthma. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Sindhu, Sardar; Koshy, Merin; Al-Roub, Areej; Akhter, Nadeem; Al Zanki, Saad; Ali, Shamsha; Devarajan, Sriraman; Ahmad, Rasheed
• Is Part Of: Journal of diabetes and metabolic disorders. Volume 15:Issue 1(2015)
• Page Start: 1
• Page End: 7
• Publication Date: 2016-12
• Subjects: Type-2 diabetes -- Asthma -- Monocyte chemoattractant protein-1 -- Inflammation -- Biomarkers; Diabetes -- Periodicals; Metabolism -- Disorders -- Periodicals; 616.462
• DOI: 10.1186/s40200-016-0264-4
• Languages: English
• ISSNs: 2251-6581

Abstract

Abstract Background Chronic inflammation is a hallmark of type-2 diabetes (T2D) and asthma. Monocyte chemoattractant protein (MCP)-1 or CCL-2 is a key regulator of monocytic infiltration into the sites of inflammation. The changes in systemic MCP-1 levels and its relationship with other inflammatory/immune markers in T2D patients with asthma remain unclear and have been addressed in this study. Methods Plasma samples from 10 asthmatic T2D patients (Group I: BMI = 37.82 ± 9.75 kg/m2 ), 13 non-asthmatic T2D patients (Group II: BMI = 32.68 ± 4.63 kg/m2 ), 23 asthma patients without T2D (Group III: BMI = 30.14 ± 6.74 kg/m2 ), and 25 non-asthmatic non-diabetic controls (Group IV: BMI = 27.99 ± 5.86 kg/m2 ) were used to measure levels of MCP-1 and multiple cytokine/chemokine biomarkers with bead-based multiplex assays using Luminex technology. IgE/ECP were measured using commercial ELISA kits. Data (mean ± SEM) were compared using unpaired Student'st -test and linear dependence between two variables was assessed by Pearson's correlation coefficient (r) andP ≤ 0.05 was considered as significant. Results Plasma MCP-1 levels were significantly higher in Group I (337.95 ± 46.40 pg/mL) as compared with Group II (216.69 ± 17.30 pg/mL), Group III (251.76 ± 19.80 pg/mL), and Group IV (223.52 ± 133.36 pg/mL). MCP-1 showed differential association with tested biomarkers by correlating positively with: (i) IFN-α2, IL-10, fractalkine, and VEGF in T2D patients with asthma; (ii) IL-6 and GRO-α in T2D patients without asthma; (iii) MDC, IP-10, GM-CSF, FGF-2, and PDGF-AA/BB in patients with asthma only; and (iv) FPG and TG in non-asthmatic non-diabetic controls. MCP-1 associated with IL-1RA only in subjects with asthma. Conclusion The systemic MCP-1 levels were significantly elevated in T2D patients with asthma as compared with those without asthma and/or diabetes while these changes correlated differentially with important biomarkers of inflammation and airway remodeling.